Literature DB >> 25370453

PharmGKB summary: very important pharmacogene information for CYP4F2.

Maria L Alvarellos1, Katrin Sangkuhl, Roxana Daneshjou, Michelle Whirl-Carrillo, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25370453      PMCID： PMC4261059          DOI： 10.1097/FPC.0000000000000100

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  63 in total

1.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Authors:  Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia
Journal:  Contemp Clin Trials       Date:  2008-09-10       Impact factor: 2.226

2.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

3.  A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men.

Authors:  Zhenyan Fu; Tomohiro Nakayama; Naoyuki Sato; Yoichi Izumi; Yuji Kasamaki; Atsushi Shindo; Masakatsu Ohta; Masayoshi Soma; Noriko Aoi; Mikano Sato; Koichi Matsumoto; Yukio Ozawa; Yitong Ma
Journal:  Am J Hypertens       Date:  2008-09-11       Impact factor: 2.689

Review 4.  Metabolism and cell biology of vitamin K.

Authors:  Martin J Shearer; Paul Newman
Journal:  Thromb Haemost       Date:  2008-10       Impact factor: 5.249

5.  Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases.

Authors:  James P Hardwick
Journal:  Biochem Pharmacol       Date:  2008-03-15       Impact factor: 5.858

6.  Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects.

Authors:  Zhenyan Fu; Tomohiro Nakayama; Naoyuki Sato; Yoichi Izumi; Yuji Kasamaki; Atsushi Shindo; Masakatsu Ohta; Masayoshi Soma; Noriko Aoi; Mikano Sato; Koichi Matsumoto; Yukio Ozawa; Yitong Ma
Journal:  Hypertens Res       Date:  2008-09       Impact factor: 3.872

7.  A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure.

Authors:  Natalie C Ward; I-Jung Tsai; Anne Barden; Frank M van Bockxmeer; Ian B Puddey; Jonathan M Hodgson; Kevin D Croft
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

8.  Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids.

Authors:  Robert-Jan Sanders; Rob Ofman; Georges Dacremont; Ronald J A Wanders; Stephan Kemp
Journal:  FASEB J       Date:  2008-01-08       Impact factor: 5.191

9.  CYP4F2 genetic variant alters required warfarin dose.

Authors:  Michael D Caldwell; Tarif Awad; Julie A Johnson; Brian F Gage; Mat Falkowski; Paul Gardina; Jason Hubbard; Yaron Turpaz; Taimour Y Langaee; Charles Eby; Cristi R King; Amy Brower; John R Schmelzer; Ingrid Glurich; Humberto J Vidaillet; Steven H Yale; Kai Qi Zhang; Richard L Berg; James K Burmester
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
View more
  6 in total

1.  Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.

Authors:  Ahmet Kocael; Allison Pınar Eronat; Mete Bora Tüzüner; Ahmet Ekmekçi; Ahmet Lütfullah Orhan; İbrahim İkizceli; Hülya Yılmaz-Aydoğan; Oğuz Öztürk
Journal:  Mol Biol Rep       Date:  2019-02-02       Impact factor: 2.316

2.  Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Authors:  Vera Kim; Thijs van der Wal; Miriam Yumie Nishi; Luciana Ribeiro Montenegro; Flair Jose Carrilho; Yujin Hoshida; Suzane Kioko Ono
Journal:  Pharmacogenomics       Date:  2020-06-03       Impact factor: 2.533

Review 3.  Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2020-05-04       Impact factor: 5.568

4.  Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.

Authors:  W Hernandez; E R Gamazon; K Aquino-Michaels; E Smithberger; T J O'Brien; A F Harralson; M Tuck; A Barbour; L H Cavallari; M A Perera
Journal:  J Thromb Haemost       Date:  2017-03-25       Impact factor: 5.824

Review 5.  Role of Genetic Variations in the Hepatic Handling of Drugs.

Authors:  Jose J G Marin; Maria A Serrano; Maria J Monte; Anabel Sanchez-Martin; Alvaro G Temprano; Oscar Briz; Marta R Romero
Journal:  Int J Mol Sci       Date:  2020-04-20       Impact factor: 5.923

6.  Personalised Medicine: implication and perspectives in the field of occupational health.

Authors:  Valentina Bollati; Luca Ferrari; Veruscka Leso; Ivo Iavicoli
Journal:  Med Lav       Date:  2020-11-25       Impact factor: 1.275
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.